Highlights

  • Mesoblast has drawn US$50 million from a five-year non-dilutive financing facility provided by existing shareholder and director Dr. Gregory George.
  • The funding will be used to retire higher-cost short-term debt owed to NovaQuest Capital Management and optimise the company's capital structure.
  • The new facility carries a fixed annual interest rate of 8.0% with a five-year interest-only period.
  • At 30 March 2026, Mesoblast held cash of US$122 million, with management stating the company is well funded for commercial operations and pipeline development.
  • Mesoblast shares were trading 4.93% lower at AUD 2.12 during the afternoon session on 25 June 2026, although the stock remains up 31.68% over the past year.

Mesoblast Limited (ASX:MSB) (NASDAQ:MESO) has drawn US$50 million under a five-year non-dilutive financing facility provided by existing shareholder and director Dr. Gregory George. The company said the new funding strengthens its capital structure by replacing higher-cost short-term debt while providing additional financial flexibility to support commercial operations and the continued development of its product pipeline.

Mesoblast shares were trading 4.93% lower at AUD 2.12 during the afternoon session on 25 June 2026. Despite today's decline, the stock remains 31.68% higher over the past year.

Mesoblast is a global biotechnology company focused on developing allogeneic, or off-the-shelf, cellular medicines for severe inflammatory diseases. The company's proprietary mesenchymal stromal cell platform is designed to modulate inflammatory responses across multiple immune pathways. Mesoblast's lead commercial product, Ryoncil® (remestemcel-L-rknd), is the first United States Food and Drug Administration (FDA)-approved mesenchymal stromal cell therapy for treating steroid-refractory acute graft-versus-host disease in paediatric patients aged two months and older.

US$50 Million Facility Drawn

The company confirmed it has accessed US$50 million from a previously announced five-year financing facility.

The facility has been provided by existing Mesoblast shareholder and director Dr. Gregory George.

Management stated that the funding is non-dilutive, meaning it does not involve the issuance of additional shares to raise capital.

According to Mesoblast, the proceeds will primarily be used to retire the company's higher-cost debt facility with NovaQuest Capital Management LLC.

The company said replacing this debt eliminates short-term debt obligations while improving the overall capital structure.

Funding Position Strengthened

Mesoblast also outlined its existing cash position.

As of 30 March 2026, the company reported cash holdings of US$122 million.

Combined with the newly drawn facility, management stated that Mesoblast remains well funded to support commercial activities together with continued investment across its development pipeline.

The company indicated that the financing supports both current operations and longer-term growth initiatives.

Lower Interest Cost and Longer Repayment Profile

The new credit facility carries a fixed annual interest rate of 8.0%.

According to Mesoblast, this represents a reduction compared with the financing arrangements it is replacing.

The facility also provides a five-year interest-only repayment period from the initial drawdown.

Unlike some financing arrangements, the company noted that the facility may be repaid at any time without early repayment penalties or make-whole fees.

No exit fees are attached to the agreement.

Mesoblast also stated that the financing is secured solely against royalties from TEMCELL®, limiting the collateral attached to the facility.

Company Retains Strategic Flexibility

Management highlighted another feature of the new financing structure.

According to the company, the facility does not place security over its principal operating assets or intellectual property portfolio.

Mesoblast said this preserves flexibility for future strategic partnerships, licensing agreements and other commercial transactions involving its technology platform.

The company believes maintaining unrestricted access to these opportunities is an important aspect of its long-term growth strategy.

Commercial Portfolio Continues to Expand

Mesoblast continues to advance multiple clinical and commercial programs based on its proprietary allogeneic stromal cell technologies.

Its approved therapy, Ryoncil®, is currently authorised in the United States for paediatric patients with steroid-refractory acute graft-versus-host disease.

Beyond its approved indication, the company is developing remestemcel-L for additional inflammatory diseases, including adult steroid-refractory acute graft-versus-host disease and biologic-resistant inflammatory bowel disease.

Another lead product candidate, rexlemestrocel-L, is under development for heart failure and chronic low back pain.

Mesoblast also maintains commercial partnerships across Japan, Europe and China.

Global Intellectual Property Supports Pipeline

The company reported that its intellectual property portfolio includes more than 1,000 granted patents and patent applications.

These cover mesenchymal stromal cell compositions, manufacturing methods and therapeutic indications.

According to Mesoblast, this portfolio provides commercial protection extending through at least 2044 across major global markets.

The company also highlighted its proprietary manufacturing processes, which are designed to produce industrial-scale, cryopreserved cellular medicines suitable for worldwide distribution.

Mesoblast currently operates across Australia, the United States and Singapore while maintaining listings on both the Australian Securities Exchange and Nasdaq.

Capital Structure Simplification

The latest financing forms part of Mesoblast's broader balance sheet strategy.

By replacing shorter-term and higher-cost debt with a longer-dated facility carrying a lower fixed interest rate, the company has extended its debt maturity profile while reducing financing costs.

Management said the revised capital structure is intended to support both ongoing commercial activities and future pipeline development without placing additional restrictions on its operating assets.

What This Means for Investors

Mesoblast's latest financing announcement focuses on strengthening the company's balance sheet rather than raising new equity. The US$50 million non-dilutive facility enables the retirement of higher-cost short-term debt while extending the repayment profile through a five-year interest-only structure. Combined with the company's reported US$122 million cash position at the end of March 2026, management believes Mesoblast is well funded to support commercial operations and the continued advancement of its cell therapy pipeline.